Canopy Growth Corp (CGC) FinancialsCGCFinancialCanopy Growth Corp

Canopy Growth Corporation (CGC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Canadian medical cannabis, accounting for 35.5% of total sales, equivalent to CAD 25.28M. Other significant revenue streams include Canadian adult-use cannabis and Storz and Bickel. Understanding this composition is critical for investors evaluating how CGC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Canopy Growth Corporation maintains a gross margin of 27.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -27.24%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CGC converts its operational activities into shareholder value.

In the context of the broader market, CGC competes directly with industry leaders such as TLRY and GLAS. With a market capitalization of $458.29M, it holds a significant position in the sector. When comparing efficiency, CGC's gross margin of 27.40% stands against TLRY's 29.93% and GLAS's 26.22%. Such benchmarking helps identify whether Canopy Growth Corporation is trading at a premium or discount relative to its financial performance.

Canopy Growth has shown fluctuating revenue, with Q1 2027 revenue reported at 81.17 million CAD, but it continues to report net losses, including a significant loss of -157.11 million CAD in Q4 2026. The gross margin has been inconsistent, with a recent figure of 25.46%.